2-(2′-((Dimethylamino)methyl)-4′-(3-[18F]fluoropropoxy)-phenylthio)benzenamine for positron emission tomography imaging of serotonin transporters

Nuclear Medicine and Biology

Volumn 35, Issue 4, 2008, Pages 447-458

  Wang, Julie L ^a   Parhi, Ajit K ^a   Oya, Shunichi ^a   Lieberman, Brian ^a   Kung, Mei Ping ^a   Kung, Hank F ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

5 HTT; Autoradiography; Binding affinity; F 18; Radioligand; Rat brain

Indexed keywords

2 [2' ((DIMETHYLAMINO)METHYL) 4' (3 [F18]FLUOROPROPOXY) PHENYLTHIO] BENZENAMINE; SEROTONIN TRANSPORTER; TRACER; 2 (2 ((DIMETHYLAMINO)METHYL) 4 (3 FLUOROPROPOXY)PHENYLTHIO)BENZENAMINE; 2-(2-((DIMETHYLAMINO)METHYL)-4-(3-FLUOROPROPOXY)PHENYLTHIO)BENZENAMINE; ANILINE DERIVATIVE; FLUORINE; RADIOPHARMACEUTICAL AGENT; SEROTONIN ANTAGONIST;

ANIMAL TISSUE; ARTICLE; AUTORADIOGRAPHY; BINDING AFFINITY; BRAIN REGION; CELL STRAIN; CEREBELLUM; CORPUS STRIATUM; HOMOGENATE; HYPOTHALAMUS; IN VITRO STUDY; IN VIVO STUDY; MALE; MESENCEPHALON; MOLECULAR IMAGING; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; RADIOACTIVITY; RAT; THALAMUS; ANIMAL; BRAIN; CHEMISTRY; DRUG EFFECT; METHODOLOGY; RADIOASSAY; SCINTISCANNING; SPRAGUE DAWLEY RAT; TISSUE DISTRIBUTION;

ANILINE COMPOUNDS; ANIMALS; AUTORADIOGRAPHY; BRAIN; FLUORINE RADIOISOTOPES; LLC-PK1 CELLS; MALE; POSITRON-EMISSION TOMOGRAPHY; RADIOLIGAND ASSAY; RADIOPHARMACEUTICALS; RATS; RATS, SPRAGUE-DAWLEY; SEROTONIN ANTAGONISTS; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS; TISSUE DISTRIBUTION;

EID: 43049168348     PISSN: 09698051     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nucmedbio.2008.02.009     Document Type: Article

References (53)

1. Siegel G.J. Basic Neurochemistry: Molecular, Cellular and Medical Aspects (1999), Lippincott Williams & Wilkins, Philadelphia
2. Kandel E.R., Schwartz J.H., and Jessell T.M. Principles of Neural Science (2000), McGraw-Hill Companies, Columbus, OH
3. Schmitt J.A., Wingen M., Ramaekers J.G., Evers E.A., and Riedel W.J. Serotonin and human cognitive performance. Curr Pharm Des 12 (2006) 2473-2486
4. Fergusson D., Doucette S., Glass K.C., Shapiro S., Healy D., Hebert P., et al. Association between suicide attempts and selective serotonin reuptake inhibitors: systematic review of randomised controlled trials. BMJ 330 (2005) 396
5. Nemeroff C.B. The burden of severe depression: a review of diagnostic challenges and treatment alternatives. J Psychiatr Res (2006)
6. DeBattista C., and Solvason H.B. When the first SSRI fails: a review of switching strategies in patients resistant to an initial SSRI. Essent Psychopharmacol 5 (2003) 217-224
7. Frazer A., and Morilak D.A. What should animal models of depression model?. Neurosci Biobehav Rev 29 (2005) 515-523
8. Maeda J., Ji B., Irie T., Tomiyama T., Maruyama M., Okauchi T., et al. Longitudinal, quantitative assessment of amyloid, neuroinflammation, and anti-amyloid treatment in a living mouse model of Alzheimer's disease enabled by positron emission tomography. J Neurosci 27 (2007) 10957-10968
9. Koerts J., Leenders K.L., Koning M., Portman A.T., and van Beilen M. Striatal dopaminergic activity (FDOPA-PET) associated with cognitive items of a depression scale (MADRS) in Parkinson's disease. Eur J Neurosci 25 (2007) 3132-3136
10. Bohnen N.I., Gedela S., Kuwabara H., Constantine G.M., Mathis C.A., Studenski S.A., et al. Selective hyposmia and nigrostriatal dopaminergic denervation in Parkinson's disease. J Neurol 254 (2007) 84-90
11. Swerdlow R.H. PET sheds light on Alzheimer's disease genetic risk. Proc Natl Acad Sci U S A 104 (2007) 18881-18882
12. Hammoud D.A., Hoffman J.M., and Pomper M.G. Molecular neuroimaging: from conventional to emerging techniques. Radiology 245 (2007) 21-42
13. Wagner HN, Jr. Molecular imaging: thriving all over the world. J Nucl Med 2007;48:15N-16N, 19N-38N.
14. Waterhouse R.N. Determination of lipophilicity and its use as a predictor of blood-brain barrier penetration of molecular imaging agents. Mol Imaging Biol 5 (2003) 376-389
15. 11C]AFM. J Cereb Blood Flow Metab 22 (2002) 1377-1398
16. 11C]McN5652: a serotonin transporter radioligand. J Cereb Blood Flow Metab 19 (1999) 967-981
17. 11C]DASB. Eur J Nucl Med 27 (2000) 1719-1722
18. 11C]-DASB: a probe for in vivo measurements of the serotonin transporter by positron emission tomography. Nucl Med Biol 29 (2002) 509-515
19. 11C-labeled 2-(phenylthio)araalkylamines. J Med Chem 43 (2000) 3103-3110
20. Oya S., Choi S.R., Hou C., Mu M., Kung M.P., Acton P.D., et al. 2-((2-((Dimethylamino)methyl)phenyl)thio)-5-iodophenylamine (ADAM): an improved serotonin transporter ligand. Nucl Med Biol 27 (2000) 249-254
21. Shiue G.G., Choi S.R., Fang P., Hou C., Acton P.D., Cardi C., et al. N,N-Dimethyl-2-(2-amino-4-(18)F-fluorophenylthio)-benzylamine (4-(18)F-ADAM): an improved PET radioligand for serotonin transporters. J Nucl Med 44 (2003) 1890-1897
22. 11C]AFM). Nucl Med Biol 31 (2004) 543-556
23. 18F]ACF (2-[(2-amino-4-chloro-5-fluorophenyl)thio]-N,N-dimethyl-benzenmethanamine). J Med Chem 45 (2002) 4716-4723
24. 11C]AFE is a selective serotonin transporter ligand with fast brain uptake kinetics. Nucl Med Biol 31 (2004) 983-994
25. Parhi A.K., Wang J.L., Oya S., Choi S.R., Kung M.P., and Kung H.F. 2-(2′-((Dimethylamino)methyl)-4′-(fluoroalkoxy)-phenylthio)benzenamine derivatives as serotonin transporter imaging agents. J Med Chem 50 (2007) 6673-6684
26. 11C]DASB imaging of serotonin transporters in patients with alcoholism. Alcohol Clin Exp Res 31 (2007) 28-32
27. 11C]DASB and positron emission tomography. Biol Psychiatry 60 (2006) 207-217
28. Guttman M., Boileau I., Warsh J., Saint-Cyr J.A., Ginovart N., McCluskey T., et al. Brain serotonin transporter binding in non-depressed patients with Parkinson's disease. Eur J Neurol 14 (2007) 523-528
29. 11C]-DASB, a tool for in vivo measurement of SSRI-induced occupancy of the serotonin transporter: PET characterization and evaluation in cats. Synapse 47 (2003) 123-133
30. 11C]DASB positron emission tomography study. Am J Psychiatry 161 (2004) 826-835
31. 11C]DASB positron emission tomography. Psychopharmacology (Berl) 193 (2007) 539-545
32. 18F]fluorobenzyl)methylamino)methylphenylsulfanyl)benzonitrile, an F-18 fluorobenzyl analogue of DASB: synthesis, in vitro binding, and in vivo biodistribution studies. Bioconjug Chem 18 (2007) 1612-1618
33. Huang Y., Bae S.A., Zhu Z., Guo N., Roth B.L., and Laruelle M. Fluorinated diaryl sulfides as serotonin transporter ligands: synthesis, structure-activity relationship study, and in vivo evaluation of fluorine-18-labeled compounds as PET imaging agents. J Med Chem 48 (2005) 2559-2570
34. Huang W., Huang S., Yeh C., Ma K., Wang H., Peng C., et al. 18F-ADAM PET in healthy and drug-naive depressant subjects. Washington DC. J Nucl Med 48 (2007) 261 Abs #1191
35. Peng C.J., Huang Y.Y., Huang W.S., and Shiue C.Y. An automated synthesis of N,N-dimethyl-2-(2-amino-4-[(18)F]fluorophenylthio)benzylamine (4-[(18)F]-ADAM) for imaging serotonin transporters. Appl Radiat Isot (2008) [in Press]
36. 123I] IDAM, 5-iodo-2-((2-((dimethylamino)methyl)phenyl)thio)benzyl alcohol. J Med Chem 42 (1999) 333-335
37. Gu H., Wall S.C., and Rudnick G. Stable expression of biogenic amine transporters reveals differences in inhibitor sensitivity, kinetics, and ion dependence. J Biol Chem 269 (1994) 7124-7130
38. 123I]IDAM as a novel single-photon emission tomography tracer for serotonin transporters. Eur J Nucl Med 26 (1999) 844-853
39. Choi S.R., Hou C., Oya S., Mu M., Kung M.P., Siciliano M., et al. Selective in vitro and in vivo binding of [(125)I]ADAM to serotonin transporters in rat brain. Synapse 38 (2000) 403-412
40. Johnson M.S., Lutz E.M., Firbank S., Holland P.J., and Mitchell R. Functional interactions between native Gs-coupled 5-HT receptors in HEK-293 cells and the heterologously expressed serotonin transporter. Cell Signal 15 (2003) 803-811
41. Kish S.J., Furukawa Y., Chang L.J., Tong J., Ginovart N., Wilson A., et al. Regional distribution of serotonin transporter protein in postmortem human brain: is the cerebellum a SERT-free brain region?. Nucl Med Biol 32 (2005) 123-128
42. Purselle D.C., and Nemeroff C.B. Serotonin transporter: a potential substrate in the biology of suicide. Neuropsychopharmacology 28 (2003) 613-619
43. Surti S., Karp J.S., Perkins A.E., Cardi C.A., Daube-Witherspoon M.E., Kuhn A., et al. Imaging performance of A-PET: a small animal PET camera. IEEE Trans Med Imaging 24 (2005) 844-852
44. Huisman M.C., Reder S., Weber A.W., Ziegler S.I., and Schwaiger M. Performance evaluation of the Philips MOSAIC small animal PET scanner. Eur J Nucl Med Mol Imaging 34 (2007) 532-540
45. Battaglino R., Fu J., Spate U., Ersoy U., Joe M., Sedaghat L., et al. Serotonin regulates osteoclast differentiation through its transporter. J Bone Miner Res 19 (2004) 1420-1431
46. Bliziotes M.M., Eshleman A.J., Zhang X.W., and Wiren K.M. Neurotransmitter action in osteoblasts: expression of a functional system for serotonin receptor activation and reuptake. Bone 29 (2001) 477-486
47. Kuge Y., Minematsu K., Hasegawa Y., Yamaguchi T., Mori H., Matsuura H., et al. Positron emission tomography for quantitative determination of glucose metabolism in normal and ischemic brains in rats: an insoluble problem by the Harderian glands. J Cereb Blood Flow Metab 17 (1997) 116-120
48. 2 knockout and wild-type mice with (11)C-raclopride and microPET. J Nucl Med 43 (2002) 1570-1577
49. Yang Y., Tai Y.C., Siegel S., Newport D.F., Bai B., Li Q., et al. Optimization and performance evaluation of the microPET II scanner for in vivo small-animal imaging. Phys Med Biol 49 (2004) 2527-2545
50. Eckelman W.C. Further discussions on choosing the number of animals for an experiment. Nucl Med Biol 35 (2008) 1-2
51. Eckelman W.C., Kilbourn M.R., Joyal J.L., Labiris R., and Valliant J.F. Justifying the number of animals for each experiment. Nucl Med Biol 34 (2007) 229-232
52. Scheibe P.O. Number of samples - hypothesis testing. Nucl Med Biol 35 (2008) 3-9
53. Wilson A.A., Patrick Johnson D., Mozley D., Hussey D., Ginovart N., Nobrega J., et al. Synthesis and in vivo evaluation of novel radiotracers for the in vivo imaging of the norepinephrine transporter. Nucl Med Biol 30 (2003) 85-92